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Advances in imaging techniques and establishmentof surveillance protocols for high-risk populationshave led to the detection of small hepatic nodules
in patients with chronic liver diseases, particularly those
with cirrhosis or chronic hepatitis caused by hepatitis B or
C viruses. These nodules, comprising a broad range of
diagnostic entities—some benign and some with malig-
nant potential—are currently deﬁned histologically, and
their clinical management often depends on the ability to
make a reliable histologic diagnosis.
Evidence accumulated in the last two decades strongly
favors the existence of a sequence of events in hepatic
nodules that precedes the emergence of hepatocellular
carcinoma (HCC),1-10 and these lesions are recognized as
precursors ofHCC.However, from the beginning of their
recognition, there has been considerable confusion con-
cerning nomenclature and diagnostic approaches to these
hepatic nodules. To clarify these issues, an International
Working Party (IWP) of the World Congresses of Gas-
troenterology proposed a consensus nomenclature and
diagnostic criteria for hepatocellular nodular lesions in
1995.11 The IWP classiﬁed nodular lesions found in
chronic liver disease into large regenerative nodule, low-
grade dysplastic nodule (L-DN), high-grade dysplastic
nodule (H-DN), and HCC; this nomenclature has been
widely adopted. In addition, the IWP introduced the con-
cept of dysplastic focus as a cluster of hepatocytes with
features of early neoplasia (in particular small cell change
or iron-free foci in a siderotic background) measuring less
than 0.1 cm, and deﬁned small HCC as a tumor measur-
ing less than 2 cm.
More recent studies support the division of small HCC
into two clinico-pathological groups that have been
termed early HCC and progressed HCC. Early HCC has
a vaguely nodular appearance and is well differentiated.
Progressed HCC has a distinctly nodular pattern and is
mostly moderately differentiated, often with evidence of
microvascular invasion.12 Early HCC has a longer time to
recurrence and a higher 5-year survival rate compared
with progressed HCC.13
Small lesions withmalignant potential have only subtle
differences from the surrounding parenchyma, making
them difﬁcult to assess reproducibly. Differences in the
application of diagnostic criteria between Western and
Eastern pathologists has been a persistent difﬁculty in
research and clinical management of these lesions.14 In
order to obtain a reﬁned and up-to-date international
consensus on the histopathologic diagnosis of nodular
lesions, such as dysplastic nodules and early HCC, the
International Consensus Group for Hepatocellular Neo-
plasia (ICGHN) was convened in April 2002 in Kurume,
Japan. The group has met several times up to July 2007
under the auspices of the Laennec Liver Pathology Soci-
ety. The ICGHN is currently comprised of 34 patholo-
gists and two clinicians from 13 countries. It includes
most members of the original IWPwho are still active and
all the participants from the ﬁrst ICGHN meeting. This
consensus document summarizes the results of our meet-
ings.
Materials and Methods
Twenty-six resected cases of nodules from 23 patients
with chronic hepatitis or cirrhosis caused by hepatitis B or
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C virus were selected from one Korean and two Japanese
medical centers. All the lesions measured less than 2 cm in
diameter. One hematoxylin and eosin–stained slide com-
prising the entire width of each lesion, a gross picture, and
brief clinical data were reviewed by each pathologist indi-
vidually, and the lesions were classiﬁed according to the
IWP criteria. The group met at Kurume University Med-
ical School, Kurume, Japan, in April 2002 to review all
the lesions with photographs and by group review of rel-
evant slides with a projecting microscope. The histologic
diagnostic criteria were discussed, focusing on cases with
marked discrepancies in initial, premeeting diagnosis.
The secondmeeting was held at the University of Leuven,
Belgium, in May 2004. The members discussed the diag-
nosis of an additional set of 22 resected small nodules.
The third meeting was held at the Aristotle University of
Thessaloniki, Greece in May 2006, and histopathologic
consensus on both dysplastic nodules and early HCC was
obtained. Kappa statistics were obtained from the com-
parative diagnostic panels of the ﬁrst two of these meet-
ings using SAS software version 8.2 (SAS Institute Inc.,
Cary, NC).
Summary of Comparative Diagnosis Data
from Two Rounds of Slide Circulation
There was little difﬁculty in agreeing on the diagnosis
of well-differentiated, small HCC of the distinctly nodu-
lar type or when the tumor was moderately differentiated
HCC (Fig. 1A). The overwhelming diagnostic challenge
was the differentiation of H-DNs from well-differenti-
ated, small HCC of the vaguely nodular type (earlyHCC)
(Fig. 1B). These lesions showed the lowest kappa value at
the ﬁrst conference with wide interobserver variation on
initial review; the variation was diminished, but not to-
tally resolved after the ﬁrst conference. Initially, Asia-
trained pathologists generally diagnosed HCC more
frequently than Western pathologists. After the ﬁrst con-
ference, this discrepancy decreased, and kappa values for
HCC rose from 0.30 to 0.49 (though with different slide
sets), with most Western pathologists ultimately agreeing
with the diagnosis of HCC. The improvement of diag-
nostic agreement after the initial conference was due to
the recognition of stromal invasion as a criterion for diag-
nosis of well-differentiated HCC. Stromal invasion is de-
ﬁned as tumor cell invasion into the portal tracts or
ﬁbrous septa within vaguely nodular lesions15,16 (Fig. 2).
Current Suggestions for Diagnostic Criteria
Gross and Radiographic Features
It is often possible to make a presumptive diagnosis of
HCC when a small lesion is distinctly nodular and is
hypervascular on contrast-enhanced imaging in the set-
ting of cirrhosis.17,18 However, errors will occur occasion-
ally with this approach. It has been reported that a small
but signiﬁcant proportion of explant livers was misdiag-
nosed as HCC.19 Any focal lesion containing a large arte-
rio-venous shunt may be hypervascular (for example,
focal nodular hyperplasia20 or similar lesions21). A hypo-
vascular lesion less than 2 cm having a vaguely nodular
appearance cannot be accurately diagnosed by gross ex-
amination or imaging. Such lesions should undergo
guided needle core biopsy.
Some small nodules have a “nodule-in-nodule” ap-
pearance either radiologically or on gross examination.22
In this situation, the subnodule usually represents de-
differentiation of the “parent” nodule. The parent nodule
may be a dysplastic nodule or well-differentiated HCC,
and the subnodule is invariably a less-differentiated le-
sion. In these situations, the entire nodule is classiﬁed by
the worst component. Typically, the less-differentiated
component is more vascular than the parent compo-
nent.23-27 However, if the parent nodule is a dysplastic
nodule and the subnodule is well-differentiatedHCC, the
subnodule may not be hypervascular, because unpaired
arteries have not yet developed. Such unpaired arteries are
small arteries (unaccompanied by bile duct) occurring
Fig. 1. (A) HCC of distinctly nodular type (progressed HCC), 12 mm in
diameter. There was no discrepancy in the diagnosis of HCC with this
growth pattern despite the small tumor size. (B) Small HCC of vaguely
nodular type (early HCC) (arrows). These lesions were often a diagnostic
problem, solved in part by recognition of the histologic features of
stromal invasion.
Fig. 2. (A) Stromal invasion in early HCC. The tumor cells (arrows) are
invading an intratumoral portal tract. (B) CK19 immunostaining of an-
other lesion. The ductular reaction (arrows) is mimicking stromal invasion
and is prominent at the stroma–parenchymal interface. Well-differenti-
ated HCC with fatty change is located at the bottom half of the image.
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outside the original portal tracts, and are indicative of
neovascularization. They have a thin muscular wall that
can be recognized in more detail via immunostaining for
-smooth muscle actin. Regardless of vascularity, a nod-
ule-in-nodule appearance suggests the presence of HCC.
Pathologic Features
Low-Grade Dysplastic Nodules. L-DNs are some-
times vaguely nodular but are often distinct from the sur-
rounding cirrhotic liver because of the presence of
peripheral ﬁbrous scar. This is not a true capsule, but
rather condensation of scarring as is seen around all cir-
rhotic nodules. L-DNs show mild increase in cell density
with a monotonous pattern, and they have no cytologic
atypia, though they may have large cell change (formerly
referred to as large cell dysplasia28). Architectural changes
beyond clearly regenerative features are not present; these
lesions do not contain pseudoglands or markedly thick-
ened trabeculae (Fig. 3). Unpaired arteries are sometimes
present in small numbers.29 Nodule-in-nodule lesions are
not present in L-DNs. L-DNs may have diffuse siderosis
or diffusely increased copper retention.
Among members of the consensus panels, there was no
serious difﬁculty in differentiating L-DNs from early
HCC. At the opposite end of the spectrum, distinction
between L-DNs and large regenerative nodules was often
found to be difﬁcult or impossible. Therefore, there is
currently consensus that distinction between these two
diagnostic categories cannot be made conﬁdently by mor-
phology alone and remains a task for the future. Fortu-
nately, this distinction does not appear to have signiﬁcant
practical consequences at present.
High-Grade Dysplastic Nodules. H-DNs may be
distinctly or vaguely nodular in the background of cirrho-
sis, although they also lack a true capsule, similar to L-
DNs; however, they are more likely to show a vaguely
nodular pattern than L-DNs. An H-DN is deﬁned as
having architectural and/or cytologic atypia, but the
atypia is insufﬁcient for a diagnosis ofHCC.These lesions
most often show increased cell density, sometimes more
than 2 times higher than the surrounding nontumoral
liver, often with an irregular trabecular pattern (Fig. 3).
Small cell change (also known as small cell dysplasia30) is
the most frequently seen form of cytologic atypia in H-
DNs. This form of atypia may also occur in small hepa-
tocellular foci outside of H-DNs; the term dysplastic
focus11 may be appropriately used for such lesions. Large
cell change may or may not be present in H-DNs. Un-
paired arteries are found in most lesions, but usually not
in great numbers. A nodule-in-nodule appearance is oc-
casionally found in H-DNs, and subnodules often have a
higher labeling index of Ki-67 or proliferating cell nuclear
antigen than that of H-DN parenchyma. When a nodule
with largely H-DN features contains a subnodule of
HCC, the subnodule of HCC is usually well-differenti-
ated with a well-deﬁned margin.
The diagnostic discrepancy between H-DN and early
HCCwas frequent at the ﬁrst consensus meeting, but was
remarkably improved at the second meeting due to the
recognition of stromal invasion as a diagnostic criterion
for the differentiation of H-DN from early HCC. If areas
of questionable invasion are present, immunostaining for
keratins 7 or 19 may be useful; if such staining demon-
strates a ductular reaction, the focus is considered a
pseudoinvasion and does not warrant a diagnosis of
HCC31 (Fig. 2B).
Early HCC (Small Well-Differentiated HCC
of Vaguely Nodular Type)
Early HCC tumors are vaguely nodular and are char-
acterized by various combinations of the following major
histologic features6,22,32 (Fig. 3):
(1) increased cell density more than 2 times that of the
surrounding tissue, with an increased nuclear/cytoplasm
ratio and irregular thin-trabecular pattern;
(2) varying numbers of portal tracts within the nodule
(intratumoral portal tracts);
(3) pseudoglandular pattern;
Fig. 3. (A) Low-grade dysplastic nodule (right two-thirds) shows mild
increase in cell density with a clearer trabecular arrangement than the
adjacent parenchyma. (B) High-grade dysplastic nodule. The cell density
in this example is more than 1.5 times higher than that in the surround-
ing tissue (upper left). Irregularity of the trabecular pattern is remarkable,
but there is no obvious inﬁltrative growth. (C, D) Small, well-differentiated
HCC of vaguely nodular type (early HCC). The tumor shows replacing
growth at the boundary (arrows), and the cell density is more than 2
times higher than that in the surrounding tissue. The tumor cells show an
irregular thin-trabecular pattern with occasional pseudoglands. Stromal
invasion was present elsewhere in the tumor.
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(4) diffuse fatty change; and
(5) varying numbers of unpaired arteries.
Among these features, diffuse fatty change is observed
in approximately 40% of cases.33 The characteristic fea-
tures of early HCC are sometimes seen in larger tumors as
well—that is, well-differentiated tumors that measure
over 2 cm and thus do not qualify for the designation of
small HCC set forth by the IWP. The prevalence of fatty
change decreases along with increasing tumor size; there-
fore, fatty change is uncommon in tumors larger than 3
cm. Fatty change is also uncommon in moderately differ-
entiated HCCs. Any of the features listed above may be
diffuse throughout the lesion or may be restricted to an
expansile subnodule (nodule-in-nodule). Most impor-
tantly, because all of these features may also be found in
H-DNs, it is important to note that stromal invasion
remains most helpful in differentiating early HCC from
H-DNs.
Emerging Tumor Markers
Alpha-fetoprotein is a well-established serum marker
for HCC. However, elevated levels are rarely found in
early HCCs. Alpha-fetoprotein is not useful as a tissue
marker because of low sensitivity (25% to 30%), even
with moderately differentiated HCC.
Glypican-3 (GPC3), a cell-surface heparan sulfate pro-
teoglycans that is secreted into the plasma, has recently
become established as a serum and tissue marker for
HCC.34-39 GPC3 immunoreactivity has a reported sensi-
tivity of 77% and speciﬁcity of 96% in the diagnosis of
small HCC; therefore, GPC3 positivity is a strong argu-
ment for malignancy.40,41 The staining pattern is usually
cytoplasmic but may be membranous or canalicular (Fig.
4). The monoclonal antibody from Biomosaics (IG12
clone) at a dilution of 1/50 to 1/100 as ampliﬁed with the
new short polymer systems (Advance [Dako], Novolink
[Novocastra], and Super-picture  [Zymed]) yields reli-
able results. Because GPC3 staining may be only focal,
additional markers or a panel of markers may be neces-
sary. GPC3 staining must be interpreted in context, be-
cause it may also be seen in regenerating hepatocytes in a
setting of hepatitis42 and in melanocytic lesions.43
Heat shock protein 70 (HSP70) belongs to a class of
genes (heat shock proteins) implicated in the regula-
tion of cell cycle progression, in apoptosis, and in tu-
morigenesis.44-46 Most HCCs are associated with
chronic inﬂammation and ﬁbrosis acting as stressful
conditions that lead to heat shock protein synthesis.
HSP70 is, in particular, a potent antiapoptotic survival
factor. Chuma et al.47 reported HSP70 as the most
abundantly up-regulated gene among a set of 12,600
genes in early HCC. Furthermore, it was signiﬁcantly
overexpressed in progressed HCC as compared with
early HCC, and in the latter as compared with precan-
cerous lesions. HSP70 immunoreactivity was recently
reported in the majority of HCCs, including early and
well-differentiated forms, but not in nonmalignant
nodules,48 thus suggesting its use as a marker of malig-
nancy. HSP70 immunoreactivity (SC-24, dilution
1:250 to 1:500 ampliﬁed with short polymer systems;
Santa Cruz Biotechnology, Santa Cruz, CA) is nucleo-
cytoplasmic and mostly focal with 70% sensitivity for
HCC detection in surgically resected specimens.49
Glutamine synthetase (GS) catalyzes the synthesis of
glutamine from glutamate and ammonia in the mamma-
lian liver49 where it has been shown to be restricted to
hepatocytes surrounding the terminal hepatic venules.50
It is known that glutamine, the end product of GS activ-
ity, is the major energy source of tumor cells.51 Most
importantly, GS is a target gene of -catenin so that its
overexpression is associated with mutations of -catenin
or with activation of this pathway.52-54 Up-regulation of
GS messenger RNA, protein, and activity were shown by
Christa et al.52 in human HCC, while Osada et al.55 re-
ported the stepwise increase in GS immunoreactivity
from precancerous lesions to early HCC to progressed
HCC. The monoclonal antibody from Chemicon Inter-
national (clone MB302) at a dilution of 1/500 to 1/1000
and ampliﬁed with a new short polymer system yields
reliable results. In order to increase its speciﬁcity as a
marker of malignancy, GS immunostaining should be
diffuse and of strong intensity, a pattern that can be seen
in 50% of HCCs, including early forms.49
The combination of more than one putative marker of
malignancy raises the overall accuracy. When applying a
panel of these three markers (GPC3, HSP70, and GS) to
resected small lesions, the ﬁnding of any two positive
markers had a sensitivity of 72% and a speciﬁcity of 100%
to detect malignancy.48 The diagnostic accuracy of this
panel of markers in liver biopsies of hepatocellular nod-
ules has not been yet tested.
Fig. 4. GPC3 expression in small, well-differentiated HCC of vaguely
nodular type (early HCC). (A) Hematoxylin-eosin stain. (B) Immunostain-
ing for GPC3 shows expression in the cytoplasm of tumor cells.
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Comment
The IWP criteria of 1995 have led to remarkable
progress in global standardization of nomenclature of
liver nodules.11 However, although these criteria have
been widely adopted, their application is challenging in
equivocal lesions. Perhaps the most signiﬁcant problem is
that most histologic criteria are arrayed on a gradual spec-
trum and cannot be easily summarized as present or ab-
sent. Additionally, the number of criteria suggested in the
literature are too numerous to achieve interobserver con-
sensus, and the diagnostic weight carried by each of these
criteria is uncertain. Frequently used criteria for malig-
nancy in other tissues, such as mitotic activity and cellular
atypia, are not represented to a signiﬁcant degree in well-
differentiated HCC. In addition, because the liver lacks a
layered structure as seen in the gastrointestinal tract, it is
difﬁcult to determine the presence of destructive growth
in early HCCs.
Despite these difﬁculties, current histologic criteria for
these nodules clearly yield reliable diagnoses at both ends
of the spectrum; most pathologists will correctly identify
nodules up to L-DN as benign, whereas even small well-
differentiated nodules with distinct nodular pattern or
small moderately differentiated HCCs will be correctly
identiﬁed asmalignant. The remaining gray zone includes
H-DN and early HCC. In evaluation of these lesions, the
presence of stromal invasion is a useful criterion of malig-
nancy.15,16 Accordingly, pathologists can decide whether
the equivocal tumor is HCC orH-DN by recognizing the
presence or absence of tumor cell invasion into the intra-
tumoral portal tracts. When obvious stromal invasion is
not found in an equivocal tumor, the lesion may be diag-
nosed as either H-DN or early HCC without detectable
invasion. The diagnosis of stromal invasion is subjective
and may require the assistance of histochemical (Victoria
Blue or reticulin stains16) and immunohistochemical
stains (keratin 7 or 19) for differentiation from pseudoin-
vasion.29 New immunohistochemical and molecular
markers are still under investigation and are likely to
prove useful.46,54,56
Role of Liver Biopsy. Regarding the application of
biopsy for small nodules, the American Association for
the Study of Liver Diseases recommends that biopsy
should be performed for nodules less than 2 cm if their
radiologic ﬁndings are not characteristic ofHCC,whereas
biopsy is not needed for lesions showing characteristic
radiologic ﬁndings.17 This recommendation has been
supported by prospective validation.18 Biopsy diagnosis
of equivocal nodules remains a challenge, because minute
biopsy specimens may not contain intratumoral portal
tracts, thus precluding the detection of stromal invasion.
Similarly, the detection of unpaired arteries, mitoses, and
various immunohistochemical markers are prone to sam-
pling error. Core liver biopsy is deﬁnitely superior to ﬁne
needle aspiration, because the specimen obtained is suit-
able for the assessment of both architectural and cytologic
features. Furthermore, the tissue block obtained provides
materials for marker studies. Fine needle aspiration is usu-
ally adequate for the evaluation of large lesions that are
likely to be moderately to poorly differentiated, where
diagnostic criteria are easier to evaluate.
Clinico-pathological Correlation. Clinical and
pathological features of early hepatocellular neoplasia are
summarized in Fig. 5. The characteristic imaging appear-
ance of HCC is a hypervascular lesion that shows washout
in the portal venous phase. This appearance is also typical
in small HCC of the distinctly nodular type and most
moderately differentiated small HCCs. Dysplastic nod-
ules andmost early HCCs are hypovascular lesions. These
classic images are explained by the anatomic features of
the lesions. Taken together, the pathologic and imaging
features deﬁne three phases in the evolution of neoplasia
in cirrhotic liver, where dysplastic nodules represent the
premalignant phase, well-differentiated HCC of the
Fig. 5. Diagram summarizing clinical and pathological correlations.
The cartoons in the top row show the anatomic changes that are found
with the evolution of fully malignant HCC. Because early HCCs grow in a
replacing pattern at the boundary, with tumor cells replacing the sur-
rounding liver cell cords, they show a vaguely nodular appearance. When
the tumors reach 1.5 to 2 cm in diameter, they tend to de-differentiate,
becoming moderately differentiated and growing in an expansile fashion
with formation of a ﬁbrous capsule. Hypovascularity, hypervascularity,
and isovascularity are understood to mean the signal intensity in the
arterial phase of contrast-enhanced imaging relative to the nontumorous
liver. Hypervascularity is related to the development of unpaired arteries,
the absence of portal vein supply, and the distinctly nodular growth. The
diagnosis must consider the context of the lesion, especially the pres-
ence of cirrhosis, the imaging ﬁndings, and the growth rate. In the
appropriate context, a lesion with decreased portal vein supply without
hypervascularity is suggestive of early HCC.
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vaguely nodular type represents early carcinoma, and
smallHCCs of the distinctly nodular type andmoderately
differentiated HCCs represent progressed carcinoma. In
the noncirrhotic liver, however, the developmental pro-
cess of HCC in humans has not been clariﬁed.
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